

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

2551-158

APPLICANT

BOZDAYI

FILING DATE

September 28, 2004

SERIAL NO.

10/509,094

GROUP

1648

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/NK/	WO 98/21317	05/1998	WIPO				
/NK/	WO 00/61758	10/2000	WIPO				
/NK/	WO 00/58477	10/2000	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/NK/	Yan, L. et al, Accession No. Q9IF40, submitted (JUN-2000), title: "Direct Submission", http://www.ncbi.nlm.nih.gov
	Stoll-Becker et al, "Transcription of Hepatitis B Virus in Peripheral Blood Mononuclear Cells from Persistently Infected Patients", Journal of Virology, July 1997, Vol. 71, No. 7, pp 5399-5407
	Gerner et al, "Hepatitis B Virus Core Promoter Mutations in Children with Multiple Anti-HBe/HBeAg Reactivations Result in Enhanced Promoter Activity", Journal of Medical Virology 59:415-423 (1999)
	Niesters et al, "Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy", J. Med. Microbiol., Vol. 51 (2002), 695-699
	Wakefield et al, "In Vitro Enzymatic Activity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutants in the Highly Conserved YMDD Amino Acid Motif Correlates with the Infectious Potential of the Proviral Genome", Journal of Virology, Nov. 1992, Vol. 66, No. 11, pp 6806-6812
	Torresi et al, "Restoration of Replication Phenotype of Lamivudine-Resistant Hepatitis B Virus Mutants by Compensatory Changes in the "Fingers" Subdomain of the Viral Polymerase Selected as a Consequence of Mutations in the Overlapping S Gene", Virology 299, 88-99 (2002)
	Delaney et al, "Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro", Antimicrobial Agents and Chemotherapy, Sept. 2002, Vol. 46, No. 9, pp 3057-3060
	Delaney et al, "Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation", Antiviral Chemistry & Chemotherapy 12:1-35
	Gaillard et al, "Kinetic Analysis of Wild-Type and YMDD Mutant Hepatitis B Virus Polymerases and Effects of Deoxyribonucleotide Concentrations on Polymerase Activity", Antimicrobial Agents and Chemotherapy, Apr. 2002, Vol. 46, No. 4, pp 1005-1013
✓	Han et al, "YMDD Motif Mutants in Hepatitis B Virus Polymerase during Lamivudine Therapy", Korean J. Genetics 24(2):219-226 (June 2002)
/NK/	Tatti et al, "Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine", Antiviral Research 55 (2002) 141-150

*Examiner

/Nicole Kinsey/

Date Considered

11/19/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	2551-158	10/509,094
(Use several sheets if necessary)	APPLICANT	
	BOZDAYI	
	FILING DATE	GROUP
	September 28, 2004	1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/NK/	2003-0124096 A1	7-2003	Locarnini			
↓	6555311	4-2003	Locarnini			
↓	2007-0042356	2-2007	Schildgen			
↓	2006-0165725	7-2006	Bozdayi			
/NK/	2006-0234212	10-2006	Bozdayi			

FOREIGN PATENT DOCUMENTS

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/NK/	1	WO 94/26904	11-1994	WIPO				
↓	29	97/40193	10/1997	WIPO				
↓	32	03/087351	10-2003	WIPO				
↓	33	2004/031224	4-2004	WIPO				
/NK/	34	03/066841	8-2003	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/NK/	13	ALEXOPOULOU A <i>et al</i> , J General Virology (1996), vol. 3, pp 173-81, "Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity" Table 3.
	27	Aye <i>et al</i> , "Hepatitis B Virus Polymerase Mutations During Famciclovir Therapy in Patients Following Liver Transplantation", Hepatology Vol. 24, No. 4, Pt.2, Abstract 633, September 1996
	30	Aye <i>et al</i> , "Hepatitis B Virus polymerase mutations during antiviral therapy in a patient following liver transplantation", Journal of Hepatology, 1997; 26: 1148-1153
	38	Bartholomeusz <i>et al</i> , "Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine", 1997, International Antiviral News, Vol. 5, No. 8, 123-124
	26	Bartholomew, "Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation", (Lancet 349: 20-22, January 1997)
	14	BOWYER S <i>et al</i> , J General Virology (1997), vol. 78, pp 1719-29, "A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa" Figure 5
	17	Carman <i>et al</i> , "Vaccine-induced escape mutant ...", The Lancet, Vol. 336, 1990 (8711) pages 325-329.
	20	Carman, "The clinical significance of surface antigen variants ...", Journal of Viral Hepatitis, 1997. 4 (Suppl. 1) 11-20.
↓	23	Chenault, "Patterns of nucleotide sequence variation among cauliflower mosaic virus isolates", (Biochimie 76:3-8, 1994)
/NK/	31	de Man <i>et al</i> , "The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globuline escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss", Journal of Hepatology, 1998; 29: 669-675

*Examiner	/Nicole Kinsey/	Date Considered	11/19/2007
-----------	-----------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	2551-158	10/509,094
(Use several sheets if necessary)	APPLICANT	
	BOZDAYI	
	FILING DATE	GROUP
	September 28, 2004	1648

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/NK/	24	Fischer et al, "Generation of Duck Hepatitis B Virus Polymerase Mutants through Site-Directed Mutagenesis Which Demonstrate Resistance to Lamivudine [(-)-β-L-2',3'-Dideoxy-3'-Thiacytidine] In Vitro", Antimicrobial Agents & Chemotherapy 40: 1957-1960, August 1996
	18	Fujii et al, "Gly ¹⁴⁵ to Arg Substitution in HBs Antigen of ...", Biochemical and Biophysical Research Communications, Vol. 184, No. 3, May 15, 1992, pages 1152-1157.
	44	Ho et al, "A Family Cluster of an Immune Escape Variant of Hepatitis B Virus Infecting a Mother and Her Two Fully Immunized Children", Clinical and Diagnostic Laboratory Immunology, 1995, Vol. 2, No. 6, pp 760-762
	9	HORIKITA M et al, J Medical Virology (1994), vol. 44(1), pp 96-103, "Differences in the entire nucleotide sequence between hepatitis B virus genomes from carriers positive for antibody to hepatitis B e antigen with and without active disease" Table IV.
	15	Ling ("Selection of mutations in hepatitis B virus polymerase during therapy of transplant recipients with lamivudine" Hepatology 24(3): 711-713, September 1996)
	10	NI F et al, Research in Virology (1995), vol. 146(6), pp 397-407, "A new immune escape mutant of hepatitis B virus with an Asp to Ala substitution in aa144 of the envelope major protein" Figure 3.
	25	Norder, "Molecular basis of hepatitis B virus serotype variations within the four major subtypes", (Virology 198: 489-503, 1994)
	46	Norder et al, "Molecular basis of hepatitis B virus serotype variations within the four major subtypes", Journal of General Virology 1992, Vol. 73, pp 3141-3145
	7	NORDER H et al, J General Virology (1992), vol. 73(5), pp 1201-8, "Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B strains" Figure 3.
	8	NORDER H et al, J General Virology (1993), vol. 74, pp 1341-8, "Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen" Figure 2.
	5	OKAMOTO F et al, J. General Virology (1988), vol 69, pp. 2575-83, "Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes" Figure 1.
	3	ONO Y et al, Nucleic Acids Research(1983), vol. 11(6), pp 1747-57, "The complete nucleotide of the cloned hepatitis B virus DNA; subtype <i>adr</i> and <i>adw</i> " Figure 2 and 3.
	2	PASEK M et al, Nature(1979), vol. 282, pp 575-9, "Hepatitis B virus genes and their expression in <i>E. Coli</i> " Figure 2.
	47	Perrillo et al, "Adefovir Dipivoxil Added to Ongoing Lamivudine in Chronic Hepatitis B with YMDD Mutant Hepatitis B Virus", Gastroenterology 2004; 126:81-90
✓	48	Poch et al, "Identification of four conserved motifs among the RNA-dependent polymerase encoding elements" EMBO Journal 8: 3867-3874, 1989
/NK/	22	Ren H et al, "Expression of 12 antibody escape mutants of hepatitis B virus surface antigen gene in mammalian cell by using an Epstein-Barr based vector", Chung Hua I Hseuh Tsa Chih 1995 75(7) pages 396-398 (PubMed English Abstract PMID 7553156).

Examiner	/Nicole Kinsey/	Date Considered	11/19/2007
----------	-----------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	2551-158	10/509,094
(Use several sheets if necessary)	APPLICANT	
	BOZDAYI	
	FILING DATE	GROUP
	September 28, 2004	1648

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/NK/	6	RIVKINA M <i>et al</i> , Gene (1988), vol. 64, pp. 285-96, "Nucleotide sequence of integrated hepatitis B virus DNA and human flanking regions in the genome of the PLC/PRF/5 cell line" Figure 5.
	50	Stuyver <i>et al</i> , "Nomenclature for Antiviral-Resistant Human Hepatitis B Virus Mutations in the Polymerase Region", Hepatology 2001; 33:751-757
	16	Tipples ("Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo" Hepatology 24(3): 714-717, September 1996)
	12	UCHIDA T <i>et al</i> , J General Virology (1995), vol. 45, pp 247-52, "Complete nucleotide sequences and the characteristics of two hepatitis B virus mutants causing serologically negative acute or chronic hepatitis B: Page 249.
	11	Uchida, T. <i>et al</i> . GenBank Accession No. D50489, TITLE: "Direct Submission" Submitted (08-MAY-1995) http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=807711
	4	VAUDIN M <i>et al</i> , J. General Virology (1988), vol. 69, pp 1383-9, "The complete nucleotide sequence of the genome of a hepatitis B virus isolated from a naturally infected chimpanzee" Figure 1.
	21	Wang GT <i>et al</i> , "Sequencing of hepatitis B virus DNA fragment coding major HBsAg of escape mutant", Chung Hua I Hseuh Tsa Chih 1994 June 74(6) pages 355-357, 391 (PubMed English Abstract PMID 7994645)
	54	Weiss <i>et al</i> , "The HBV-Producing Cell Line HepG2-4A5: A new <i>in vitro</i> system for studying the regulation of HBV replication and for screening anti-hepatitis B virus drugs", Virology 216:214-218, 1 February 1996
	55	Werle <i>et al</i> "Evolution of hepatitis B virus load and viral genome sequence during adefovir dipivoxil therapy" 2004, Journal of Viral Hepatitis, vol 11, No. 1, pages 74-83
	19	Yamamoto <i>et al</i> , "Naturally Occurring Escape Mutants of Hepatitis B Virus with ...", Journal of Virology, Vol. 68, No. 4, April, 1994, pages 2671-2676.
	57	Blum, "Variants of Hepatitis B, C and D Viruses: Molecular Biology and Clinical Significance", Digestion (1995); 56:85-95
	58	Kidd-Ljunggren, "Variability in Hepatitis B Virus DNA: Phylogenetic, Epidemiological and Clinical Implications", Scand J Infect Dis 28:111-116 (1996)
	59	Kan Tan Sui, "Escape Mutants of HBs" (1993), 27(4), pp 555-562
	60	H. Uetake Ed., Virology, 4 th Ed., ver.1, Rikougaku-sha (publ.), July 10, 2002, p 452 (in Japanese) (Relevance noted in Doc. No. 61)
	61	Aoyama & Partners letter dated February 15, 2007, relating to Japanese Patent Application No. 521944/1998 (4 pages)
↓	62	Aoyama & Partners letter dated January 25, 2007, relating to Japanese Patent Application No. 521944/1998 (2 pages)
/NK/	63	Aoyama & Partners letter dated July 23, 2007, relating to Japanese Patent Application No. 521944/1998 (1 page) with English translation of amended claims (2 pages) and copy of Amendment filed July 19, 2007, in response to Official Action (11 pages)

*Examiner	/Nicole Kinsey/	Date Considered	11/19/2007
-----------	-----------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)